Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pivotal Phase 3, Clinical Trial of Chikungunya Vaccine (MV-CHIK)

Next Previous
Search
Trial Profile

A Pivotal Phase 3, Clinical Trial of Chikungunya Vaccine (MV-CHIK)

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 20 Apr 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Chikungunya virus vaccine (Primary)
  • Indications Chikungunya virus infections
  • Focus Registrational; Therapeutic Use
  • Sponsors Themis Bioscience

    • Most Recent Events

    • 13 Jun 2019 New trial record
    • 04 Jun 2019 According to a Themis Bioscience media release, clinical trial applications will be submitted to regulatory authorities in the second half of 2019, with the trial initiation expected shortly thereafter.
    • 04 Jun 2019 According to a Themis Bioscience media release, Themis Bioscience and the Coalition for Epidemic Preparedness Innovations (CEPI) announced a second partnering agreement under which CEPI, with support from the European Unions Horizon 2020 programme, will provide up to US dollar 21 million of non-dilutive capital for the Phase 3-ready Chikungunya vaccine (MV-CHIK).The agreement will provide a significant portion of the capital required for this trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top